JP2023540490A5 - - Google Patents
Info
- Publication number
- JP2023540490A5 JP2023540490A5 JP2023514117A JP2023514117A JP2023540490A5 JP 2023540490 A5 JP2023540490 A5 JP 2023540490A5 JP 2023514117 A JP2023514117 A JP 2023514117A JP 2023514117 A JP2023514117 A JP 2023514117A JP 2023540490 A5 JP2023540490 A5 JP 2023540490A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- heavy chain
- light chain
- olimbacimab
- pembrolizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073512P | 2020-09-02 | 2020-09-02 | |
| US63/073,512 | 2020-09-02 | ||
| US202063122321P | 2020-12-07 | 2020-12-07 | |
| US63/122,321 | 2020-12-07 | ||
| PCT/IB2021/058043 WO2022049526A1 (en) | 2020-09-02 | 2021-09-02 | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023540490A JP2023540490A (ja) | 2023-09-25 |
| JP2023540490A5 true JP2023540490A5 (enExample) | 2024-08-21 |
Family
ID=77914405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514117A Pending JP2023540490A (ja) | 2020-09-02 | 2021-09-02 | がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230265196A1 (enExample) |
| EP (1) | EP4208482A1 (enExample) |
| JP (1) | JP2023540490A (enExample) |
| KR (1) | KR20230087451A (enExample) |
| AU (1) | AU2021337223A1 (enExample) |
| CA (1) | CA3189987A1 (enExample) |
| MX (1) | MX2023002570A (enExample) |
| WO (1) | WO2022049526A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260116273A (ko) | 2024-09-20 | 2026-07-28 | 파라곤 테라퓨틱스, 인크. | Pd-1 결합 단백질, vegf 및 pd-1 이중특이적 결합 단백질, 조성물 및 사용 방법 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| PT1916001E (pt) | 2002-03-04 | 2011-07-18 | Imclone Llc | Anticorpos humanos específicos para kdr e suas utilizações |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2012135408A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EP3463456A1 (en) * | 2016-06-03 | 2019-04-10 | ImClone LLC | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
-
2021
- 2021-09-02 KR KR1020237010758A patent/KR20230087451A/ko active Pending
- 2021-09-02 WO PCT/IB2021/058043 patent/WO2022049526A1/en not_active Ceased
- 2021-09-02 CA CA3189987A patent/CA3189987A1/en active Pending
- 2021-09-02 MX MX2023002570A patent/MX2023002570A/es unknown
- 2021-09-02 EP EP21777846.3A patent/EP4208482A1/en active Pending
- 2021-09-02 US US18/043,602 patent/US20230265196A1/en active Pending
- 2021-09-02 JP JP2023514117A patent/JP2023540490A/ja active Pending
- 2021-09-02 AU AU2021337223A patent/AU2021337223A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512851A5 (enExample) | ||
| JP2025016606A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| HRP20231156T1 (hr) | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka | |
| JP2017501157A5 (enExample) | ||
| JP2021501162A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2020503260A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| JP2021513540A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2017507652A5 (enExample) | ||
| JP2019502676A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2015534579A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| JP2017507900A5 (enExample) | ||
| JP2018505177A5 (enExample) | ||
| JP2023524149A5 (enExample) | ||
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2024541680A5 (enExample) | ||
| JP2015517529A5 (enExample) |